This HTML5 document contains 117 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n6http://dx.doi.org/10.1007/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q83965064
rdf:type
wikibase:Item
schema:description
наукова стаття, опублікована у квітні 2012 scientific article published on 17 April 2012 wetenschappelijk artikel im April 2012 veröffentlichter wissenschaftlicher Artikel artículu científicu espublizáu n'abril de 2012 article scientifique publié en 2012
p:P577
wds:Q83965064-6C91BBBC-8DE6-4B93-A066-E34041EE06FD
wdt:P577
2012-04-17T00:00:00Z
p:P2860
wds:Q83965064-08E6D3FB-9DF0-453F-BFDD-DC1C7C3FFC10 wds:Q83965064-0BD6A6B1-1782-4E04-8CB3-63C991DDB617 wds:Q83965064-13BA25F4-BBE0-48A1-97B1-6EB15501F25A wds:Q83965064-1E46C575-1803-43F0-B7FA-17609B0A5CC8 wds:Q83965064-2E316790-FED1-4E4C-9EC9-6F9B3AAEA1CF wds:Q83965064-2FB74ACC-39E6-4357-83E2-F5BB0731F221 wds:Q83965064-460623B6-02D1-45EB-BD3A-72C7CB3B8D3F wds:Q83965064-5DEFDEF9-E356-4A9C-B7BA-C9C243008301 wds:Q83965064-6555FE21-270A-447E-86B0-B40FAD0A7C15 wds:Q83965064-78350CB2-57FF-4A10-B132-AF3F55CDEA1D wds:Q83965064-84078E92-CF79-405D-96DD-0CF6826AC47C wds:Q83965064-968E61B7-6C64-4985-8C42-6F17E3CE2F8D wds:Q83965064-A253EB98-AC4F-4F08-9F1C-23E0D8D296B1 wds:Q83965064-AAA43B24-708A-4505-835B-ACBA45C026A5 wds:Q83965064-AC3FBCB9-A975-49F4-8780-5BF4CD0B5723 wds:Q83965064-B2304B9A-FA1D-4983-88ED-BBC5B548426D wds:Q83965064-B8AF76DC-878E-485B-BA64-515DD5F83BA0 wds:Q83965064-BBA4B330-AFA4-4053-8898-C26D4C2EFC23 wds:Q83965064-C0921BA7-9489-4B92-8F8A-51CDCEA42446 wds:Q83965064-CEC931D3-446C-46A2-98D8-DDBA16A6D7C4 wds:Q83965064-D3CB91D1-2EAF-4052-99D2-DD4675999B6B wds:Q83965064-D6AEB9F6-CFC9-48E6-A593-873061DA9FB4 wds:Q83965064-EEFEE91E-E2AB-4ED9-A685-D66C8DD2E846
wdt:P2860
wd:Q28168615 wd:Q43293550 wd:Q28171316 wd:Q34430052 wd:Q41997560 wd:Q72219865 wd:Q45939747 wd:Q37235086 wd:Q35051637 wd:Q28192693 wd:Q43233434 wd:Q35116433 wd:Q81061006 wd:Q28210388 wd:Q28193290 wd:Q42167071 wd:Q28218361 wd:Q42783586 wd:Q28214020 wd:Q43259672 wd:Q46476290 wd:Q43285639 wd:Q83496725
p:P2093
wds:Q83965064-EC2CA56E-6EE3-4785-98FA-2E81612C2147 wds:Q83965064-E8654F23-47BE-4848-89F9-88FA7C08995D wds:Q83965064-B98928A1-EB9C-4408-880C-75D3BE36A70F wds:Q83965064-A865433E-7969-42E4-9842-FEBC40B41525 wds:Q83965064-D93EF8BF-892E-4369-8D05-8DFFE7BAAFD4 wds:Q83965064-D14FB09E-B7D9-4B06-8FDA-E4B8360A9EE6 wds:Q83965064-C68818D0-F952-453E-81C1-02733A179DA7 wds:Q83965064-613F2D5F-9E07-4910-AC48-CB47A1E254E8 wds:Q83965064-5B04E187-CF30-4244-AF58-B0FA3E64783F wds:Q83965064-9C4816F9-E51E-4416-BA15-257D59514547 wds:Q83965064-9C21629A-A70B-416A-B5C5-D30CED0281C7 wds:Q83965064-7D1B701A-C721-4A6B-A27C-AF183518C3F6 wds:Q83965064-1D636872-5010-4834-BBA7-E83AC0C81805 wds:Q83965064-11755AEB-3FCE-4CE6-90AC-C66446E36E19 wds:Q83965064-42A01E1F-A6B1-4327-935C-2509F240C627 wds:Q83965064-26798C14-2B56-4B5D-973C-0E6D66355AF0
wdt:P2093
Yukinao Yamazaki Care Study Group Hideto Inokuchi Shuichi Terao Hideki Miyaji Takanobu Hayakumo Manabu Murakami Hiromu Kutsumi Shun-ichi Yoshida Takashi Kawai Takeshi Azuma Tsuyoshi Sanuki Hajime Kuwayama Tsuyoshi Fujita Takashi Fujisawa Yoshihiro Matsubara
rdfs:label
Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial
skos:prefLabel
Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial
schema:name
Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial
p:P1476
wds:Q83965064-CD1D320F-7D4A-456E-8AFC-CE9FF5EE62DF
wdt:P1476
Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial
p:P304
wds:Q83965064-964EB7C6-8996-49BF-AEDA-A1B5F3C7DCB1
wdt:P304
1186-1197
p:P31
wds:Q83965064-97E5E6EA-F36C-4C6F-B443-04764FA5D078
wdt:P31
wd:Q13442814
p:P921
wds:Q83965064-A715E441-A2BF-4FF9-8594-8AD32E040486 wds:Q83965064-2363701F-FB35-4B15-9900-675851596565 wds:Q83965064-1D860F1E-15B2-42B4-9396-DCEF6FD5BE3D
wdt:P921
wd:Q18216 wd:Q3010352 wd:Q3515
p:P698
wds:Q83965064-50E3EE51-FEBC-4457-B739-48B9C31B7103
wdtn:P698
n12:22526273
wdt:P698
22526273
p:P1433
wds:Q83965064-0F27EF46-C830-46B2-BEFF-8C93D3AA9992
wdt:P1433
wd:Q15764399
p:P433
wds:Q83965064-4C7E19CD-A31D-48DF-85CE-97C4F9595B38
p:P478
wds:Q83965064-E9228911-769D-41A2-B7A9-C82025F8B0AF
wdt:P433
11
wdt:P478
47
p:P356
wds:Q83965064-40AE6A65-21EE-46FD-9E00-A4C72630B213
wdtn:P356
n6:S00535-012-0588-X
wdt:P356
10.1007/S00535-012-0588-X